Charles River Laboratories International (NYSE:CRL) Price Target Raised to $322.00

Charles River Laboratories International (NYSE:CRL) had its price objective raised by Royal Bank Of Canada from $282.00 to $322.00 in a research report sent to investors on Friday morning, MarketBeat Ratings reports. They currently have an outperform rating on the medical research company’s stock.

A number of other research firms have also commented on CRL. Barclays upped their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the company an “overweight” rating in a research note on Friday. TD Cowen lifted their target price on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday. Evercore restated an “outperform” rating and set a $320.00 price target on shares of Charles River Laboratories International in a report on Friday, September 11th. Argus set a $330.00 price target on shares of Charles River Laboratories International in a research report on Thursday, September 17th. Finally, Mizuho raised their price objective on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research note on Friday. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $287.06.

Charles River Laboratories International Stock Down 0.1%

Shares of Charles River Laboratories International stock opened at $292.49 on Friday. The stock’s fifty day moving average is $270.45 and its 200-day moving average is $213.29. The firm has a market capitalization of $13.96 billion, a PE ratio of -60.31, a price-to-earnings-growth ratio of 2.85 and a beta of 1.40. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International has a 12-month low of $145.32 and a 12-month high of $303.30.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period in the prior year, the business posted $3.12 earnings per share. Charles River Laboratories International’s revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts anticipate that Charles River Laboratories International will post 11.42 earnings per share for the current year.

Insider Activity

In other news, EVP Victoria Creamer sold 4,179 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James Foster sold 33,561 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $9,478,800. This represents a 51.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 90,990 shares of company stock worth $25,731,388. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Continuum Advisory LLC purchased a new stake in Charles River Laboratories International in the 2nd quarter worth approximately $30,000. SHP Wealth Management purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $85,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $104,000. Trust Asset Management LLC acquired a new position in shares of Charles River Laboratories International in the second quarter worth $129,000. Finally, Hilltop National Bank increased its stake in shares of Charles River Laboratories International by 28.7% in the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock worth $129,000 after acquiring an additional 127 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analysts raised their price targets. Royal Bank of Canada lifted its target from $282 to $322 and maintained an “outperform” rating, while Robert W. Baird raised its target from $291 to $334 and also rated CRL “outperform.” These revisions imply roughly 10% to 14% additional upside from the referenced price.
• Positive Sentiment: Investor Day provided stronger long-term growth visibility. Charles River reaffirmed its fiscal 2026 revenue outlook at approximately $3.9 billion and raised EPS guidance to $11.45, above the $11.33 analyst consensus. The company also introduced 2030 growth targets, helping drive a recent rally in the stock. Charles River Laboratories Stock Rises 6% After Unveiling 2030 Growth Targets
• Positive Sentiment: Investor reaction has been favorable. Reports indicated CRL rose about 5% to 6% following the company’s Investor Day presentation, reflecting investor confidence in the updated 2026 outlook and longer-term targets. Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
• Neutral Sentiment: Mizuho raised its target but remained cautious. The firm increased its target from $264 to $295 but kept a “neutral” rating, suggesting limited upside from the referenced price and a more balanced risk-reward assessment.
• Negative Sentiment: Some of the good news may already be priced in. An investor analysis characterized the Investor Day as positive but argued that the improved outlook is fully reflected in CRL’s valuation. This may explain why the stock has decreased modestly despite favorable announcements. Charles River Laboratories: Positive Investor Day Is Fully Priced In

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.